Table 4.
Clinical characteristics of cardiovascular-related adverse events
Etomidate group (n = 90) | Propofol group (n = 90) | P-value | Significance | |
---|---|---|---|---|
Tachycardia, n (%) | 0 (0.00) | 0 (0.00) | NA | n.s. |
Transient hypertension, n (%) | 6 (6.67) | 1 (1.11) | 0.118 | n.s. |
Bradycardia, n (%) | 2 (2.22) | 4 (4.44) | 0.682 | n.s. |
Transient hypotension, n (%) | 1 (1.11) | 8 (8.89) | 0.034 | * |
n.s.: no significance; *P<0.05.